Multiomics Analysis Identifies Key Genes and Pathways Related to N6-Methyladenosine RNA Modification in Ovarian Cancer

References

• Torre LA , IslamiF , SiegelRLet al. Global cancer in women: burden and trends. Cancer Epidemiol. Biomarkers. Prev.26(4), 444–457 (2017).
   PubMed Web of Science ®Google Scholar
• Webb PM , JordanSJ. Epidemiology of epithelial ovarian cancer. Best. Pract. Res. Clin. Obstet. Gynaecol.41, 3–14 (2017).
   PubMed Web of Science ®Google Scholar
• Lheureux S , GourleyC , VergoteI , OzaAM. Epithelial ovarian cancer. Lancet.393(10177), 1240–1253 (2019).
   PubMed Web of Science ®Google Scholar
• Dominissini D , Moshitch-MoshkovitzS , SchwartzSet al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature.485(7397), 201–206 (2012).
   PubMed Web of Science ®Google Scholar
• Wang X , ZhaoBS , RoundtreeIAet al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell.161(6), 1388–1399 (2015).
   PubMed Web of Science ®Google Scholar
• Wang X , LuZ , GomezAet al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature.505(7481), 117–120 (2014).
   PubMed Web of Science ®Google Scholar
• Xiao W , AdhikariS , DahalUet al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol. Cell.61(4), 507–519 (2016).
   PubMed Web of Science ®Google Scholar
• Sun T , WuR , MingL. The role of m6A RNA methylation in cancer. Biomed. Pharmacother.112, 108613 (2019).
   PubMed Web of Science ®Google Scholar
• Wang P , DoxtaderKA , NamY. Structural basis for cooperative function of METTL3 and METTL14 methyltransferases. Mol. Cell.63(2), 306–317 (2016).
   PubMed Web of Science ®Google Scholar
• Ping XL , SunBF , WangLet al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell. Res.24(2), 177–189 (2014).
   PubMed Web of Science ®Google Scholar
• He L , LiH , WuA , PengY , ShuG , YinG. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer.18(1), 176 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang S , ZhaoBS , ZhouAet al. m6A Demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 Expression and cell proliferation program. Cancer Cell.31(4), 591–606.e6 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao X , YangY , SunBFet al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell. Res.24(12), 1403–1419 (2014).
   PubMed Web of Science ®Google Scholar
• Casella G , TsitsipatisD , AbdelmohsenK , GorospeM. mRNA methylation in cell senescence. Wiley. Interdiscip. Rev. RNA10(6), e1547 (2019).
   PubMed Web of Science ®Google Scholar
• Arguello AE , DeLibertoAN , KleinerRE. RNA chemical proteomics reveals the N6-methyladenosine (m6A)-regulated protein-RNA interactome. J. Am. Chem. Soc.139(48), 17249–17252 (2017).
   PubMed Web of Science ®Google Scholar
• Chen XY , ZhangJ , ZhuJS. The role of m6A RNA methylation in human cancer. Mol. Cancer18(1), 103 (2019).
   PubMed Web of Science ®Google Scholar
• Wang S , ChaiP , JiaR , JiaR. Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword. Mol. Cancer17(1), 101 (2018).
   PubMed Web of Science ®Google Scholar
• He L , LiJ , WangXet al. The dual role of N6-methyladenosine modification of RNAs is involved in human cancers. J. Cell. Mol. Med.22(10), 4630–4639 (2018).
   PubMed Web of Science ®Google Scholar
• Hua W , ZhaoY , JinXet al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol. Oncol.151(2), 356–365 (2018).
   PubMed Web of Science ®Google Scholar
• Liang S , GuanH , LinXet al. METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol. Lett.19(4), 3197–3204 (2020).
   PubMed Web of Science ®Google Scholar
• Ma Z , LiQ , LiuPet al. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell. Biol. Int.44(12), 2524–2531 (2020).
   PubMed Web of Science ®Google Scholar
• Bi X , LvX , LiuDet al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer. Gene. Ther.28(3–4), 335–349 (2021).
   PubMed Web of Science ®Google Scholar
• Yu HL , MaXD , TongJF et al. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco. Targets. Ther.12, 6191–6201 (2019).
   PubMed Web of Science ®Google Scholar
• Fukumoto T , ZhuH , NacarelliTet al. N6-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer. Res.79(11), 2812–2820 (2019).
   PubMed Web of Science ®Google Scholar
• Huang H , WangY , KandpalMet al. FTO-dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer. Res.80(16), 3200–3214 (2020).
   PubMed Web of Science ®Google Scholar
• Zhao L , KongX , ZhongWet al. FTO accelerates ovarian cancer cell growth by promoting proliferation, inhibiting apoptosis, and activating autophagy. Pathol. Res. Pract.216(9), 153042 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu H , GanX , JiangXet al. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J. Exp. Clin. Cancer. Res.38(1), 163 (2019).
   PubMedGoogle Scholar
• Jiang Y , WanY , GongM et al. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumor microenvironment through stimulating NF-κB pathway. J. Cell. Mol. Med.24(11), 6137–6148 (2020).
   PubMed Web of Science ®Google Scholar
• Hao L , WangJM , LiuBQet al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim. Biophys. Acta. Mol. Cell. Res.1868(1), 118878 (2021).
   PubMed Web of Science ®Google Scholar
• Liu T , WeiQ , JinJet al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic. Acids. Res.48(7), 3816–3831 (2020).
   PubMed Web of Science ®Google Scholar
• Li J , WuL , PeiM , ZhangY. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J. Ovarian. Res.13(1), 111 (2020).
   PubMed Web of Science ®Google Scholar
• Müller S , GlaßM , SinghAKet al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic. Acids. Res.47(1), 375–390 (2019).
   PubMed Web of Science ®Google Scholar
• Fukumoto T , ZhuH , NacarelliTet al. N6-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer. Res.79(11), 2812–2820 (2019).
   PubMed Web of Science ®Google Scholar
• Visvanathan A , PatilV , AroraAet al. Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance. Oncogene.37(4), 522–533 (2018).
   PubMed Web of Science ®Google Scholar
• Yan F , Al-KaliA , ZhangZet al. A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell. Res.28(11), 1062–1076 (2018).
   PubMed Web of Science ®Google Scholar
• Zhou S , BaiZL , XiaDet al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol. Carcinog.57(5), 590–597 (2018).
   PubMed Web of Science ®Google Scholar
• Huang Y , YanJ , LiQet al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic. Acids. Res.43(1), 373–384 (2015).
   PubMed Web of Science ®Google Scholar
• Cui Q , ShiH , YePet al. m6A RNA Methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell. Rep.18(11), 2622–2634 (2017).
   PubMed Web of Science ®Google Scholar
• Huang Y , SuR , ShengYet al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer. Cell.35(4), 677–691.e10 (2019).
   PubMed Web of Science ®Google Scholar
• Yoshihara K , TsunodaT , ShigemizuDet al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer. Res.18(5), 1374–1385 (2012).
   PubMed Web of Science ®Google Scholar
• Winterhoff B , HamidiH , WangCet al. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol. Oncol.141(1), 95–100 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang B , WuQ , LiBet al. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol. Cancer19(1), 53 (2020).
   PubMed Web of Science ®Google Scholar
• Cerami E , GaoJ , DogrusozUet al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer. Discov.2(5), 401–404 (2012).
   PubMed Web of Science ®Google Scholar
• Bindea G , MlecnikB , HacklHet al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics25(8), 1091–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Szklarczyk D , GableAL , LyonDet al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids. Res.47(D1), D607–D613 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou Y , ZengP , LiYHet al. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids. Res.44(10), e91 (2016).
   PubMed Web of Science ®Google Scholar
• Newman AM , LiuCL , GreenMRet al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods12(5), 453–457 (2015).
   PubMed Web of Science ®Google Scholar
• Mariathasan S , TurleySJ , NicklesDet al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature554(7693), 544–548 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang Q , CaiY , KurbatovVet al. Gene alterations of N6-methyladenosine (m6A) regulators in colorectal cancer: a TCGA database study. Biomed. Res. Int.2020, 8826456 (2020).
   PubMed Web of Science ®Google Scholar
• Wang X , HanY , LiJet al. Multi-omics analysis of copy number variations of RNA regulatory genes in soft tissue sarcoma. Life Sci.265, 118734 (2021).
   PubMed Web of Science ®Google Scholar
• Wang P , WangX , ZhengL , ZhuangC. Gene signatures and prognostic values of m6A Regulators in Hepatocellular Carcinoma. Front. Genet.11, 540186 (2020).
   PubMedGoogle Scholar
• Shi H , ZhaoJ , HanLet al. Retrospective study of gene signatures and prognostic value of m6A regulatory factor in non-small cell lung cancer using TCGA database and the verification of FTO. Aging (Albany NY)12(17), 17022–17037 (2020).
   PubMedGoogle Scholar
• Zhou J , WangJ , HongBet al. Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma – a retrospective study using TCGA database. Aging (Albany NY).11(6), 1633–1647 (2019).
   PubMedGoogle Scholar
• Li Y , GuJ , XuFet al. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma. Brief. Bioinform.22(4), bbaa225 (2021).
   PubMed Web of Science ®Google Scholar
• Kwok CT , MarshallAD , RaskoJE , WongJJ. Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia. J. Hematol. Oncol.10(1), 39 (2017).
   PubMedGoogle Scholar
• Schlesinger M . Role of platelets and platelet receptors in cancer metastasis. J. Hematol. Oncol.11(1), 125 (2018).
   PubMed Web of Science ®Google Scholar
• Bull Phelps SL , SchorgeJO , PeytonMJet al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol. Oncol.109(3), 411–417 (2008).
   PubMed Web of Science ®Google Scholar
• Levina V , NolenBM , MarrangoniAMet al. Role of eotaxin-1 signaling in ovarian cancer. Clin. Cancer. Res.15(8), 2647–2656 (2009).
   PubMed Web of Science ®Google Scholar
• Charles KA , KulbeH , SoperRet al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest.119(10), 3011–3023 (2009).
   PubMed Web of Science ®Google Scholar
• Li C , LiuVW , ChiuPM, et al. Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol. Cancer13, 49 (2014).
   PubMed Web of Science ®Google Scholar
• Yu Y , ZhangX , HongSet al. Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells. J. Ovarian. Res.7, 39 (2014).
   PubMed Web of Science ®Google Scholar
• Yu Y , ZhangM , ZhangXet al. Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells. J. Exp. Clin. Cancer Res.33(1), 85 (2014).
   PubMedGoogle Scholar
• Lin S , ChoeJ , DuPet al. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell62(3), 335–345 (2016).
   PubMed Web of Science ®Google Scholar
• Fang R , ChenX , ZhangSet al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat. Commun.12(1), 177 (2021).
   PubMed Web of Science ®Google Scholar
• Zhong L , LiaoD , ZhangMet al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer. Lett.442, 252–261 (2019).
   PubMed Web of Science ®Google Scholar
• Pancholi S , LykkesfeldtAE , HilmiCet al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr. Relat. Cancer.15(4), 985–1002 (2008).
   PubMed Web of Science ®Google Scholar
• Ikuta M , KornienkoM , ByrneNet al. Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein. Sci.16(12), 2626–2635 (2007).
   PubMed Web of Science ®Google Scholar
• Milosevic N , KühnemuthB , MühlbergLet al. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Neoplasia15(12), 1354–1362 (2013).
   PubMed Web of Science ®Google Scholar
• Pancholi S , LykkesfeldtAE , HilmiCet al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr. Relat. Cancer.15(4), 985–1002 (2008).
   PubMed Web of Science ®Google Scholar
• Serra V , EichhornPJ , García-GarcíaCet al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J. Clin. Invest.123(6), 2551–2563 (2013).
   PubMed Web of Science ®Google Scholar
• Slattery ML , LundgreenA , HerrickJS , WolffRK. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat. Res.706(1–2), 13–20 (2011).
   PubMed Web of Science ®Google Scholar
• Bignone PA , LeeKY , LiuYet al. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene26(5), 683–700 (2007).
   PubMed Web of Science ®Google Scholar
• Piechaczyk M , FarràsR. Regulation and function of JunB in cell proliferation. Biochem. Soc. Trans.36(Pt 5), 864–867 (2008).
   PubMedGoogle Scholar
• Neyns B , Katesuwanasing , VermeijJet al. Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene12(6), 1247–1257 (1996).
   PubMed Web of Science ®Google Scholar
• Zheng H , ZhangM , MaSet al. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients. Cancer. Med.9(14), 5200–5209 (2020).
   PubMed Web of Science ®Google Scholar
• Eckhoff K , FlurschützR , TrillschFet al. The prognostic significance of Jun transcription factors in ovarian cancer. J. Cancer. Res. Clin. Oncol.139(10), 1673–1680 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng Z , HeZ , CaiYet al. Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell. Res.29(2), 124–135 (2019).
   PubMed Web of Science ®Google Scholar
• Xu C , OoiWF , QamraAet al. HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. Gut69(2), 231–242 (2020).
   PubMed Web of Science ®Google Scholar
• Jung SY , PappJC , SobelEMet al. Pro-inflammatory cytokine polymorphisms in ONECUT2 and HNF4A and primary colorectal carcinoma: a post genome-wide gene-lifestyle interaction study. Am. J. Cancer. Res.10(9), 2955–2976 (2020).
   PubMed Web of Science ®Google Scholar
• Sugai M , UmezuH , YamamotoTet al. Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol. Int.58(11), 681–686 (2008).
   PubMed Web of Science ®Google Scholar
• Wang X , QinW , XuXet al. Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation. Proc. Natl. Acad. Sci. USA114(17), 4483–4488 (2017).
   PubMed Web of Science ®Google Scholar
• Wang X , HuLP , QinWTet al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat. Commun.12(1), 174 (2021).
   PubMed Web of Science ®Google Scholar
• Wang H , WangX , XuLet al. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets. Purinergic. Signal.16(3), 347–366 (2020).
   PubMed Web of Science ®Google Scholar
• Fan S , GaoX , QinQet al. Association between tumor mutation burden and immune infiltration in ovarian cancer. Int. Immunopharmacol.89(Pt A), 107126 (2020).
   PubMedGoogle Scholar
• Feng X , TangR , ZhangRet al. A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. J. Cell. Mol. Med.24(9), 5238–5248 (2020).
   PubMed Web of Science ®Google Scholar
• Odunsi K . Immunotherapy in ovarian cancer. Ann. Oncol.28(Suppl. 8), viii1–viii7 (2017).
   PubMedGoogle Scholar
• Zhang L , Conejo-GarciaJR , KatsarosDet al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Hartl CA , BertschiA , PuertoRBet al. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. J. Immunother. Cancer7(1), 199 (2019).
   PubMedGoogle Scholar
• Lundgren S , BerntssonJ , NodinBet al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J. Ovarian. Res.9, 21 (2016).
   PubMed Web of Science ®Google Scholar
• Kroeger DR , MilneK , NelsonBH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer. Res.22(12), 3005–3015 (2016).
   PubMed Web of Science ®Google Scholar
• Gouveia-Fernandes S . Monocytes and macrophages in cancer: unsuspected roles. Adv. Exp. Med. Biol.1219, 161–185 (2020).
   PubMed Web of Science ®Google Scholar
• Prat M , LeNaour A , CoulsonKet al. Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. J. Immunother. Cancer.8(1), e000472 (2020).
   PubMed Web of Science ®Google Scholar